Retrophin to Present at Upcoming Investor Conferences

SAN DIEGO, May 30, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming investor conferences in June:

Jefferies 2019 Global Healthcare ConferenceDate: Tuesday, June 4, 2019Time: 10:30 a.m. ETLocation: New York City

William Blair 2019 Growth Stock ConferenceDate: Thursday, June 6, 2019Time: 10:00 a.m. CT (11:00 a.m. ET)Location: Chicago

JMP Securities Life Sciences ConferenceDate: Thursday, June 20, 2019Time: 2:00 p.m. ETLocation: New York City

BMO 2019 Prescriptions for Success Healthcare ConferenceDate: Tuesday, June 25, 2019Time: 10:00 a.m. ETLocation: New York City

Live webcasts will be available at http://ir.retrophin.com/events and archived replays will be accessible for up to 30 days.

About Retrophin

Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including fosmetpantotenate for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including a joint development arrangement evaluating the potential of CNSA-001 in phenylketonuria (PKU), a rare genetic metabolic condition that can lead to neurological and behavioral impairment. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam® and Thiola®.

Retrophin.com

Contact:Chris Cline, CFA Vice President, Investor Relations & Corporate Communications760-260-8600[email protected]

You May Also Be Interested In

• William Blair Downgrades Enovix Corporation (ENVX) to Market Perform
• Focus Graphite Chairman Converts Final C$835,000 Loan to Equity at a Premium to Market
• Harbour BioMed Announces NMPA Approval of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors